Latest news
FDA approves Reckitt’s new Mucinex cold, flu medicine - NJBIZNJBIZ · Fri, 07 Aug 2026 17:06:25 GMTReckitt Benckiser Group rises Friday, outperforms market - MarketWatchMarketWatch · Fri, 07 Aug 2026 16:07:00 GMTReckitt Benckiser: Core Brands Remain Undervalued Despite Mead Johnson Litigation Risk - Seeking AlphaSeeking Alpha · Fri, 07 Aug 2026 05:34:28 GMTReckitt announces U.S. FDA approval of Mucinex 12HR Cold & Fever Multi-Symptom, the first OTC innovation in the cold & flu category in 14 years - reckitt.comreckitt.com · Wed, 05 Aug 2026 13:09:07 GMTReckitt kicks off £150M first tranche of £500M buyback with Citi - DealroomDealroom · Wed, 05 Aug 2026 11:17:44 GMTReckitt Benckiser Group (LON:RKT) Given New GBX 5,352 Price Target at Berenberg Bank - MarketBeatMarketBeat · Wed, 05 Aug 2026 10:08:45 GMTReckitt Announces Any and All Tender Offer and Consent Solicitation for Mead Johnson Nutrition Company Notes due 2044 - PR NewswirePR Newswire · Wed, 05 Aug 2026 10:07:00 GMTShould you buy shares in Reckitt Benckiser? - The TimesThe Times · Wed, 05 Aug 2026 08:21:10 GMT